Dondey Joanne C, Staffieri Sandra, McKenzie John, Davie Gabrielle, Elder James
Department of Ophthalmology, The Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia.
Clin Exp Ophthalmol. 2004 Aug;32(4):354-9. doi: 10.1111/j.1442-9071.2004.00836.x.
To describe changes in the management of retinoblastoma in Victoria and to review the effect of newer, conservative treatments on preservation of eyes, visual outcome and mortality by comparing a similar group of patients treated over successive time intervals.
A retrospective analysis of all cases of retinoblastoma diagnosed and treated in Victoria between 1956 and 2000 was conducted. Historical data on 77 cases previously published by O'Day et al. was used for the period 1956-1976 (series 1). Data on 88 cases recorded in the Royal Children's Hospital (Melbourne) Retinoblastoma Database was used for the period 1976-2000. The latter group was subdivided into those treated between 1976 and 1989 (series 2), prior to the advent of modern eye saving treatments, and those treated subsequent to their introduction from 1990 to 2000 (series 3).
In unilateral retinoblastoma, final enucleation rates for 1956-1976 (series 1) and 1976-1989 (series 2) were almost identical, being 98% and 97% of affected eyes, respectively (P = 1.00). Despite the newer treatments used after 1990 (series 3), 88% of affected eyes were still enucleated, representing a statistically similar outcome to series 2 (P = 0.33). In bilateral retinoblastoma, primary enucleation of the more involved eye was similar for series 1 (84%) and 2 (80%) but series 3 (41%) was substantially less than series 2 (P = 0.04) following the increased use of conservative treatments. In series 3, 59% of more involved eyes were treated conservatively compared with 16% (P = 0.007) and 20% (P = 0.04) for series 1 and 2, respectively. Despite attempts at eye salvage, the failure rate was higher in series 3 (29%) yielding a final enucleation rate of 70%, which represented a modest downward trend in the numbers of eyes finally enucleated; 84% (series 1), 73% (series 2) and 70% (series 3) (test for trend, P = 0.33). Bilateral enucleation rates were significantly lower, from 36% and 30% in series 1 and 2, respectively, to 7% in series 3 (test for trend, P = 0.02). As a consequence, more eyes were preserved over time, being 20/50 (40%) in series 1, 15/30 (50%) in series 2 and 21/34 (62%) in series 3. Comparison of visual outcome was hampered by incomplete data in series 1 but it appeared series 2 and 3 achieved better visual acuities with 67% and 62% of preserved eyes in bilateral cases measuring equal to or better than 6/12. Mortality rates in all series were low, being 7.8% in series 1, 4.5% in series 2 and nil in series 3.
Following the introduction of new conservative treatments, there has been an increase in preservation of eyes and improved visual outcome, and a dramatic decrease in numbers of bilateral enucleations without adversely affecting survival.
描述维多利亚州视网膜母细胞瘤治疗管理的变化,并通过比较连续时间段内治疗的相似患者群体,回顾更新的保守治疗对眼球保留、视觉预后和死亡率的影响。
对1956年至2000年间在维多利亚州诊断和治疗的所有视网膜母细胞瘤病例进行回顾性分析。奥代等人先前发表的77例病例的历史数据用于1956 - 1976年期间(系列1)。墨尔本皇家儿童医院视网膜母细胞瘤数据库记录的88例病例的数据用于1976 - 2000年期间。后一组又细分为1976年至1989年期间治疗的病例(系列2),这是在现代保眼治疗出现之前,以及1990年至2000年引入这些治疗后治疗的病例(系列3)。
在单侧视网膜母细胞瘤中,1956 - 1976年(系列1)和1976 - 1989年(系列2)的最终眼球摘除率几乎相同,分别为患眼的98%和97%(P = 1.00)。尽管1990年后采用了更新的治疗方法(系列3),但仍有88%的患眼被摘除,这在统计学上与系列2的结果相似(P = 0.33)。在双侧视网膜母细胞瘤中,系列1(84%)和系列2(80%)中受累较重眼的初次眼球摘除率相似,但在增加使用保守治疗后,系列3(41%)明显低于系列2(P = 0.04)。在系列3中,59%的受累较重眼采用了保守治疗,而系列1和系列2分别为16%(P = 0.007)和20%(P = 0.04)。尽管尝试进行眼球挽救,但系列3中的失败率更高(29%),最终眼球摘除率为70%,这表明最终摘除眼球的数量呈适度下降趋势;系列1为84%,系列2为73%,系列3为70%(趋势检验,P = 0.33)。双侧眼球摘除率显著降低,从系列1的36%和系列2的30%分别降至系列3的7%(趋势检验,P = 0.02)。因此,随着时间的推移,保留的眼球更多,系列1中为20/50(40%),系列2中为15/30(50%),系列3中为21/34(62%)。系列1中不完整的数据妨碍了视觉预后的比较,但系列2和系列3似乎获得了更好的视力,双侧病例中分别有67%和62%保留的眼球视力等于或优于6/12。所有系列的死亡率都很低,系列1为7.8%,系列2为4.5%,系列3为零。
在引入新的保守治疗方法后,眼球保留增加,视觉预后改善,双侧眼球摘除数量显著减少,且对生存率没有不利影响。